FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy

FBXW7 (F-box and WD repeat domain containing 7) is a critical subunit of the Skp1-Cullin1-F-box protein (SCF), acting as an E3 ubiquitin ligase by ubiquitinating targeted protein. Through degradation of its substrates, FBXW7 plays a pivotal role in drug resistance in tumor cells and shows the potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shimin, Lin, Jichun, Zhao, Jiaojiao, Lin, Qian, Liu, Jia, Wang, Qiang, Mui, Ryan, Ma, Leina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043335/
https://www.ncbi.nlm.nih.gov/pubmed/36998461
http://dx.doi.org/10.3389/fonc.2023.1147239
_version_ 1784913123629596672
author Chen, Shimin
Lin, Jichun
Zhao, Jiaojiao
Lin, Qian
Liu, Jia
Wang, Qiang
Mui, Ryan
Ma, Leina
author_facet Chen, Shimin
Lin, Jichun
Zhao, Jiaojiao
Lin, Qian
Liu, Jia
Wang, Qiang
Mui, Ryan
Ma, Leina
author_sort Chen, Shimin
collection PubMed
description FBXW7 (F-box and WD repeat domain containing 7) is a critical subunit of the Skp1-Cullin1-F-box protein (SCF), acting as an E3 ubiquitin ligase by ubiquitinating targeted protein. Through degradation of its substrates, FBXW7 plays a pivotal role in drug resistance in tumor cells and shows the potential to rescue the sensitivity of cancer cells to drug treatment. This explains why patients with higher FBXW7 levels exhibit higher survival times and more favorable prognosis. Furthermore, FBXW7 has been demonstrated to enhance the efficacy of immunotherapy by targeting the degradation of specific proteins, as compared to the inactivated form of FBXW7. Additionally, other F-box proteins have also shown the ability to conquer drug resistance in certain cancers. Overall, this review aims to explore the function of FBXW7 and its specific effects on drug resistance in cancer cells.
format Online
Article
Text
id pubmed-10043335
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100433352023-03-29 FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy Chen, Shimin Lin, Jichun Zhao, Jiaojiao Lin, Qian Liu, Jia Wang, Qiang Mui, Ryan Ma, Leina Front Oncol Oncology FBXW7 (F-box and WD repeat domain containing 7) is a critical subunit of the Skp1-Cullin1-F-box protein (SCF), acting as an E3 ubiquitin ligase by ubiquitinating targeted protein. Through degradation of its substrates, FBXW7 plays a pivotal role in drug resistance in tumor cells and shows the potential to rescue the sensitivity of cancer cells to drug treatment. This explains why patients with higher FBXW7 levels exhibit higher survival times and more favorable prognosis. Furthermore, FBXW7 has been demonstrated to enhance the efficacy of immunotherapy by targeting the degradation of specific proteins, as compared to the inactivated form of FBXW7. Additionally, other F-box proteins have also shown the ability to conquer drug resistance in certain cancers. Overall, this review aims to explore the function of FBXW7 and its specific effects on drug resistance in cancer cells. Frontiers Media S.A. 2023-03-14 /pmc/articles/PMC10043335/ /pubmed/36998461 http://dx.doi.org/10.3389/fonc.2023.1147239 Text en Copyright © 2023 Chen, Lin, Zhao, Lin, Liu, Wang, Mui and Ma https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Chen, Shimin
Lin, Jichun
Zhao, Jiaojiao
Lin, Qian
Liu, Jia
Wang, Qiang
Mui, Ryan
Ma, Leina
FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy
title FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy
title_full FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy
title_fullStr FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy
title_full_unstemmed FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy
title_short FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy
title_sort fbxw7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043335/
https://www.ncbi.nlm.nih.gov/pubmed/36998461
http://dx.doi.org/10.3389/fonc.2023.1147239
work_keys_str_mv AT chenshimin fbxw7attenuatestumordrugresistanceandenhancestheefficacyofimmunotherapy
AT linjichun fbxw7attenuatestumordrugresistanceandenhancestheefficacyofimmunotherapy
AT zhaojiaojiao fbxw7attenuatestumordrugresistanceandenhancestheefficacyofimmunotherapy
AT linqian fbxw7attenuatestumordrugresistanceandenhancestheefficacyofimmunotherapy
AT liujia fbxw7attenuatestumordrugresistanceandenhancestheefficacyofimmunotherapy
AT wangqiang fbxw7attenuatestumordrugresistanceandenhancestheefficacyofimmunotherapy
AT muiryan fbxw7attenuatestumordrugresistanceandenhancestheefficacyofimmunotherapy
AT maleina fbxw7attenuatestumordrugresistanceandenhancestheefficacyofimmunotherapy

Ejemplares similares